Key result
Colchicine shows no benefit over usual care for 12-month arrhythmia freedom in post-ablation acute pericarditis.
Why the study?
While colchicine has demonstrated anti-inflammatory and anti-arrhythmic effects in acute pericarditis, its efficacy in cases specifically developing after catheter ablation remained unknown.
Does colchicine reduce the recurrence rate of arrhythmias in patients who develop acute pericarditis after catheter ablation?
Does colchicine reduce the recurrence rate of arrhythmias in patients who develop acute pericarditis after catheter ablation?
The addition of colchicine to usual care does not significantly improve freedom from arrhythmias in patients who develop acute pericarditis following catheter ablation.
Acute pericarditis is a complication associated with radiofrequency or cryo-energy catheter ablation (CA) for arrhythmias and may be accompany pericardial effusion. A frequent complication of acute pericarditis is the onset of arrhythmias. While colchicine has demonstrated both anti-inflammatory and anti-arrhythmic effects in acute pericarditis, its efficacy in cases specifically developing post-CA remains unknown. The purpose of this study is to determine whether colchicine administration after the diagnosis of acute pericarditis due to CA is associated with a reduction in the recurrence rate of arrhythmias. Patients who developed acute pericarditis after CA for arrhythmias were retrospectively included in this study. Following the CA procedure, a group of patients was prescribed 0.5 mg of colchicine twice daily for 14 days at the operator's discretion, in addition to usual care. The primary outcome was freedom from arrhythmias within 12 months. Secondary outcomes included signs of pericarditis, recurrence of pericardial effusion, and the incidence of constrictive pericarditis. Among the 75 consecutively enrolled patients, acute pericarditis occurred after: pulmonary vein isolation ( n = 50), endocardial ventricular tachycardia ablation ( n = 18), right outflow premature ventricular contraction ablation ( n = 5), and atrioventricular nodal re-entrant tachycardia ablation ( n = 2). During a median follow-up of 365.0 days (IQR 333.0–420.0 days), freedom from any arrhythmia (regardless of anti-arrhythmic drug use) was similar between groups (76.2% in the colchicine group vs. 74.1% in the usual care group; log-rank p = 0.93). Univariate analysis showed that colchicine use was not associated with a lower risk of arrhythmia recurrence. No cases of recurrent pericarditis or constrictive pericarditis were observed in either group during the follow-up period. Colchicine, when added to usual care, doesn't appear associated with improved clinical outcomes in patients who developed acute pericarditis following CA for arrhythmias. Clinical trial number: UD5684993756.
No takes yet. Share an insight, caveat, or question.
Toniolo et al. (2026) studied this question. Colchicine added to usual care did not improve 12-month freedom from arrhythmias compared to usual care alone (76.2% vs. 74.1%, p=0.93) in patients with acute pericarditis after catheter ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: